Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma

Japanese Journal of Clinical Oncology

Volumn 41, Issue 11, 2011, Pages 1277-1281

  Liu, Yao Chung ^a   Chang, Peter Mu Hsin ^a,b   Liu, Chun Yu ^a,b   Yang, Chih Yu ^a,b   Chen, Ming Han ^b   Pan, Chin Chen ^a   Chen, Ming Huang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Nephrotic syndrome; Sunitinib; Transcription factor E3; Xp11.2 translocation renal cell carcinoma

Indexed keywords

CAPECITABINE; EVEROLIMUS; GEMCITABINE; SUNITINIB; TRANSCRIPTION FACTOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CHROMOSOME 11P; CHROMOSOME TRANSLOCATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENE FUSION; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEPHROTIC SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, X; COMBINED MODALITY THERAPY; FEMALE; GENE FUSION; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEPHRECTOMY; NEPHROTIC SYNDROME; PYRROLES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 80155124132     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr140     Document Type: Article

References (21)

1. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005;23:363-78.
2. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004;28:1117-32.
3. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2008;32:656-70.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
6. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer 2008;112:1607-16.
7. Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006;24:1529-34.
8. Cao Y, Paner GP, Perry KT, Flanigan RC, Campbell SC, Picken MM. Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Arch Pathol Lab Med 2005;129:487-91.
9. Meyer PN, Clark JI, Flanigan RC, Picken MM. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007;128:70-9.
10. Argani P, Ladanyi M. Renal carcinomas associated with Xp11.2 translocations/tfe3 gene fusions. In: Eble JN, Sauter G, Epstein JI, Sesterhnn I, editors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press 2004; 37-8.
11. Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocation/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol 2005;8:168-80.
12. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003;27:750-61.
13. Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol [Epub ahead of print 15 December 2010].
14. Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol 2009;2:172-6.
15. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
16. Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D, et al. Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-8.
17. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
18. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
19. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-8.
20. Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med 2010;134:124-9.
21. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007;67:919-29.